Sunday 18 October 2026 Export FENC’s income statement to Excel — free account

Adherex Technologies Inc.

Adherex Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 million, down 6.09% from fiscal 2024. In the quarter to June 2026, revenue grew 85.2%, EPS grew 154.6% and free cash flow grew 101.4%, each against the same quarter a year earlier.

9.98 0.37 −3.57%

Follow FENC

Alert me

Market cap: $362.9M
P/E: 0.0×
Fwd P/E: 31.4×
Dividend yield: —
F-score: 1/9
Altman Z: 0.51
Beneish M: −1.29
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 11.90

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	3	2	1	1	1	1	2	1	1	3	2	—

Insider Ownership 12.81%

Capital & Financial Ratios $m

Market Cap 362.94

Revenue 59.22

Net Income (3.25)

Free Cash Flow (2.04)

Net Debt (41.25)

Current Ratio 5.85

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E 31.40

P/S ratio 5.82

P/B ratio 8.12

Past 5Y EPS Growth —

This Y EPS Growth 180.95%

Next Y EPS Growth 232.35%

Next Y revenue growth 62.54%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 48.43%

10-year low 10-year high

P/B against its own 10 years 51.80%

10-year low 10-year high

EV/Sales against its own 10 years 46.01%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	13	27	37	41
Receivables	9	13	23	23
Inventory	2	1	2	2
Other	0	0	2	2
	27	44	67	73

	2023	2024	2025	Q'26
Payables	4	3	5	6
ST’ Debt	—	—	—	—
Other	—	0	0	3
	8	7	11	12

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	207.52%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	51.74%	4.06%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	15	18	—	—	—
’25	9	10	12	14	45
’24	25	7	7	8	48
’23	2	3	7	10	21
’22	—	—	—	2	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	2	0	—	—	—
’25	(4)	(4)	1	(6)	(12)
’24	39	(8)	(2)	(1)	27
’23	(6)	(4)	(3)	(5)	(17)
’22	(3)	(3)	(5)	(7)	(18)
’21	(4)	(4)	(3)	(3)	(14)
’20	(4)	(3)	(5)	(3)	(16)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	2	0	—	—	—
’25	(4)	(4)	1	(6)	(12)
’24	39	(8)	(2)	(1)	27
’23	(6)	(4)	(3)	(5)	(17)
’22	(3)	(3)	(5)	(7)	(18)
’21	(4)	(4)	(3)	(3)	(14)
’20	(4)	(3)	(5)	(3)	(16)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.01	0.05	—	—	—
’25	(0.04)	(0.11)	(0.02)	(0.17)	(0.35)
’24	0.41	(0.20)	(0.21)	(0.06)	(0.02)
’23	(0.23)	(0.21)	(0.07)	(0.10)	(0.60)
’22	(0.14)	(0.19)	(0.31)	(0.26)	(0.90)
’21	(0.18)	(0.15)	(0.16)	(0.18)	(0.67)
’20	(0.19)	(0.21)	(0.24)	(0.13)	(0.76)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	1.09	1.94	5.33	3.26	4.65	3.82	4.11	6.30	3.96	4.68	Analyst estimates 2026–2028 Powerpack
	High	3.06	13.95	14.99	7.65	10.67	10.08	10.38	11.92	11.49	9.92
People
People	Employees	3	3	3	4	9	10	36	29	32	35
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.02	0.00	0.04	0.73	1.49	1.28
Income, $m
Income, $m	Revenue	—	—	—	—	0	—	2	21	48	45
	Gross margin, %	—	—	—	—	100.00	—	94.40	94.08	93.30	91.57
	EBT	(3)	(7)	(10)	(13)	(18)	(17)	(24)	(16)	0	(10)
	EBT margin, %	0.00	0.00	0.00	0.00	(10,652.35)	0.00	(1,544.30)	(75.50)	(0.15)	(21.58)
	Net income	(3)	(7)	(10)	(13)	(18)	(17)	(24)	(16)	0	(10)
	Depreciation	—	—	—	0	0	0	0	0	1	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.01	0.00	0.06	0.80	1.74	1.56
	Earnings	(0.22)	(0.47)	(0.50)	(0.64)	(0.76)	(0.67)	(0.90)	(0.60)	(0.02)	(0.35)
	Cash flow	(0.17)	(0.24)	(0.41)	(0.46)	(0.66)	(0.55)	(0.69)	(0.65)	0.99	(0.44)
	Capex	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(0.17)	(0.24)	(0.41)	(0.46)	(0.66)	(0.55)	(0.69)	(0.65)	0.99	(0.44)
	Book value	0.28	1.78	1.13	0.60	1.23	0.61	(0.10)	(0.44)	(0.22)	1.24
	Shares, m	13	15	19	20	24	26	26	27	27	29
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	—	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	0.00	—	0.00	13.90	3.63	4.93
	P/B	—	—	—	—	6.07	—	0.00	0.00	0.00	6.20
	EV/Sales	—	—	—	—	0.00	—	0.00	14.68	3.45	4.52
	EV/FCF	—	—	—	—	(9.38)	—	(14.70)	(18.20)	6.09	(16.16)
Cash, $m
Cash, $m	Operating cash flow	(2)	(4)	(8)	(9)	(16)	(14)	(18)	(17)	27	(12)
	Capex	—	—	—	—	—	—	—	—	—	—
	Free cash flow	(2)	(4)	(8)	(9)	(16)	(14)	(18)	(17)	27	(12)
Balance, $m
Balance, $m	Working capital	4	27	21	12	29	21	22	19	37	57
	Total debt	—	—	—	—	—	5	25	30	18	—
	Net debt	(4)	(28)	(23)	(14)	(30)	(16)	1	16	(9)	(37)
	Shareholders’ equity	4	27	21	12	29	16	(3)	(12)	(6)	35
Returns, %
Returns, %	ROA	(111.76)	(43.53)	(38.51)	(68.88)	(79.49)	(64.45)	(96.10)	(59.64)	(1.21)	(16.87)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(165.56)	0.00	0.00
	ROE	(135.45)	(46.47)	(41.14)	(76.99)	(88.46)	(77.36)	(359.22)	226.13	4.98	(65.82)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RZLT Rezolute, Inc.	$377.2M	— (loss-making)	—	—	n/m	+40.23% (above 0%: growing)	0.00%	0.00%	Compare
EDIT Editas Medicine, Inc.	$374.7M	— (loss-making)	— (loss-making)	+232.31% (above 0%: growing)	n/m	+40.72% (above 0%: growing)	100.00%	(156.05%)	Compare
GALT Galectin Therapeutics Inc.	$374.2M	— (loss-making)	—	—	n/m	+63.06% (above 0%: growing)	0.00%	0.00%	Compare
KYTX Kyverna Therapeutics, Inc.	$369.2M	— (loss-making)	— (loss-making)	—	n/m	−27.06% (below 0%: shrinking)	—	0.00%	Compare
AVIR Atea Pharmaceuticals, Inc.	$363.3M	— (loss-making)	— (loss-making)	+295.16% (above 0%: growing)	n/m	+85.53% (above 0%: growing)	0.00%	0.00%	Compare
FENC Adherex Technologies Inc.	$362.9M	— (loss-making)	31.4×	+85.18% (above 0%: growing)	n/m	+101.36% (above 0%: growing)	95.97%	9.72%
TTRX Turn Therapeutics Inc.	$345.3M	— (loss-making)	—	—	n/m	−74.76% (below 0%: shrinking)	—	0.00%	Compare
OBIO Orchestra BioMed Holdings, Inc.	$345.0M	— (loss-making)	— (loss-making)	−89.47% (below 0%: shrinking)	n/m	−25.87% (below 0%: shrinking)	71.59%	(25,404.55%)	Compare
CCCC C4 Therapeutics, Inc.	$342.0M	— (loss-making)	— (loss-making)	+2.75% (above 0%: growing)	n/m	+86.84% (above 0%: growing)	100.00%	(397.88%)	Compare
Median of peers	$366.3M	—	—	+117.53%	—	+40.48%	35.80%	0.00%

All 614 Biotechnology stocks →

Adherex Technologies Inc. (FENC) key facts

Concern: Adherex Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 million, down 6.09% from fiscal 2024.
Adherex Technologies Inc. (FENC) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, FENC traded at $9.98, a market capitalization of $362.9 million.
Return on equity was −65.8% and debt-to-equity 0.00.
Its Piotroski F-score is 1 out of 9 and its Altman Z-score is 0.51 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.